Skip to content

A study comparing Unani medicine and Autologous Serum Therapy for treating chronic urticaria

An Open Label, Randomized Clinical Trial of Unani Formulation and Autologous Serum Therapy (AST) in the management of Shara-e-Muzmin (Chronic Urticaria) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/071481
Enrollment
64
Registered
2024-07-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

Intervention1: Qurse Kafoor and Sharbate Nilofar: Patients of group I will be given 1 tablet of Qurse Kafoor twice daily with Sharbate Nilofar 20ml twice daily orally for 6 weeks Control Intervention1

Sponsors

Department of Amraze Jild wa Zohrawiya Ajmal Khan Tibbiya College and Hospital AMU Aligarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Clinically diagnosed patients of Chronic Urticaria (Urticaria of more than 6 weeks); with clinical features of erythema, itching and wheals of any grade. • Patients of either sex in the age group of 18 years onwards. • Patients who have agreed to sign the written informed consent and follow the protocol.

Exclusion criteria

Exclusion criteria: • Patients with other skin diseases like psoriasis, eczema, etc. by history and examination. • Patients of urticaria presenting with features of angioedema. • Patients suffering from any other systemic diseases, such as HTN, DM, IHD, HIV, and bronchial asthma will be excluded on the basis of history and examination. • Pregnant and lactating women. • Patient already taking modern medicine or will be included in the study after a washout period of 2 weeks. • In case of worsening of the symptoms, the patient will be shifted to the standard management.

Design outcomes

Primary

MeasureTime frame
UAS7- Weekly urticaria activity score[5,11]- •Itching- 0: None, 1: Mild (no discomfort), 2: Moderate (annoying but no impact on daily activities, sleep), 3: Intense (severe itching, interferes daily activities and sleep). •Wheals- 0: No wheals, 1: Mild (less than 20 wheals per 24 hours), 2: Moderate (20-50 wheals per 24 hours), 3: Intense (more than 50 wheals per 24 hours) or large confluent areas of wheals. Timepoint: weekly for six weeks

Secondary

MeasureTime frame
CUQ2OL- Chronic urticaria quality of life questionnaire[8,9,12]- • Quality of life of the patient- It contains 23 questions, with scores from 1 (no complaints) to 5 (many complaints). Scores = 3 are considered as poor quality of life.Timepoint: weekly for six weeks

Countries

India

Contacts

Public ContactYusra Tanveer

Department of Amraze Jild Wa Zohrawiya, Faculty of Unani Medicine

drzamiramrohi@gmail.com8475007594

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026